Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
9.37
+0.57 (6.48%)
Oct 30, 2025, 12:12 PM EDT - Market open
Verastem Employees
Verastem had 78 employees as of December 31, 2024. The number of employees increased by 5 or 6.85% compared to the previous year.
Employees
78
Change (1Y)
5
Growth (1Y)
6.85%
Revenue / Employee
$27,397
Profits / Employee
-$2,135,321
Market Cap
576.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | 48 | -87 | -64.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VSTM News
- 6 days ago - Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors - Business Wire
- 7 days ago - Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 - Business Wire
- 11 days ago - Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma - Business Wire
- 23 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - Business Wire
- 2 months ago - Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire